EA201170218A1 - Лечение воспалительных заболеваний бета-дефенсинами млекопитающих - Google Patents
Лечение воспалительных заболеваний бета-дефенсинами млекопитающихInfo
- Publication number
- EA201170218A1 EA201170218A1 EA201170218A EA201170218A EA201170218A1 EA 201170218 A1 EA201170218 A1 EA 201170218A1 EA 201170218 A EA201170218 A EA 201170218A EA 201170218 A EA201170218 A EA 201170218A EA 201170218 A1 EA201170218 A1 EA 201170218A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- defensins
- treatment
- beta
- mammals
- inflammatory diseases
- Prior art date
Links
- 102000012265 beta-defensin Human genes 0.000 title abstract 2
- 108050002883 beta-defensin Proteins 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160761 | 2008-07-18 | ||
| EP08162486 | 2008-08-15 | ||
| EP08163614 | 2008-09-03 | ||
| EP09160448 | 2009-05-15 | ||
| PCT/EP2009/059251 WO2010007165A2 (en) | 2008-07-18 | 2009-07-17 | Treatment of inflammatory diseases with mammal beta defensins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170218A1 true EA201170218A1 (ru) | 2011-08-30 |
Family
ID=41445843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170218A EA201170218A1 (ru) | 2008-07-18 | 2009-07-17 | Лечение воспалительных заболеваний бета-дефенсинами млекопитающих |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100016232A1 (OSRAM) |
| EP (1) | EP2320929B1 (OSRAM) |
| JP (1) | JP2011528332A (OSRAM) |
| KR (2) | KR20110031962A (OSRAM) |
| CN (1) | CN102159232A (OSRAM) |
| AP (1) | AP2011005537A0 (OSRAM) |
| AR (1) | AR072524A1 (OSRAM) |
| AU (1) | AU2009272680A1 (OSRAM) |
| BR (1) | BRPI0915780A2 (OSRAM) |
| CA (1) | CA2730674A1 (OSRAM) |
| CL (1) | CL2011000098A1 (OSRAM) |
| EA (1) | EA201170218A1 (OSRAM) |
| IL (1) | IL210714A0 (OSRAM) |
| MX (1) | MX2011000569A (OSRAM) |
| NZ (1) | NZ590466A (OSRAM) |
| TW (1) | TW201004641A (OSRAM) |
| WO (1) | WO2010007165A2 (OSRAM) |
| ZA (1) | ZA201100462B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2320928B1 (en) * | 2008-07-18 | 2012-11-07 | Novozymes Adenium Biotech A/S | Treatment of rheumatoid arthritis with human beta defensins |
| WO2010007166A2 (en) | 2008-07-18 | 2010-01-21 | Novozymes A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| KR101883797B1 (ko) | 2010-04-15 | 2018-08-30 | 마린 폴리머 테크놀로지스, 인코퍼레이션. | 폴리-ｎ-아세틸글루코사민 나노섬유의 항-세균성 용도 |
| KR101257228B1 (ko) * | 2010-06-16 | 2013-04-29 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP3501284A1 (en) * | 2011-04-15 | 2019-06-26 | Marine Polymer Technologies, Inc. | Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers |
| JP6219277B2 (ja) | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| US20130052213A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| JP6151981B2 (ja) * | 2013-06-18 | 2017-06-21 | 一般社団法人健康科学リソースセンター | 関節リウマチ患者における生物学的製剤の有効性の予測方法 |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| GB201603653D0 (en) * | 2016-03-02 | 2016-04-13 | Cambridge Entpr Ltd | Combination Therapy |
| RU2740913C2 (ru) | 2016-04-29 | 2021-01-21 | Дефенсин Терапьютикс Апс | Лечение нарушений со стороны печени, желчных путей и поджелудочной железы |
| CN110290799A (zh) * | 2016-12-13 | 2019-09-27 | 防御素治疗学公司 | 用于治疗肺部炎性病症的方法 |
| KR102631543B1 (ko) * | 2018-03-14 | 2024-02-01 | 서울대학교산학협력단 | 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도 |
| KR102631542B1 (ko) | 2018-03-14 | 2024-02-01 | 서울대학교산학협력단 | 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도 |
| WO2020046002A1 (ko) * | 2018-08-31 | 2020-03-05 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| KR102244161B1 (ko) | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| CA3249846A1 (en) | 2022-01-28 | 2023-08-03 | Kenvue Brands Llc | Predictive Biomarkers for Atopic Dermatitis |
| WO2023194839A1 (en) | 2022-04-04 | 2023-10-12 | Donnelly | Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| MXPA05006359A (es) * | 2002-12-19 | 2006-02-08 | Yitzchak Hillman | Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos. |
| GB0514482D0 (en) * | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
| WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
| JP5491396B2 (ja) * | 2007-09-11 | 2014-05-14 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのデフェンシンペプチドの使用 |
| EP2320928B1 (en) * | 2008-07-18 | 2012-11-07 | Novozymes Adenium Biotech A/S | Treatment of rheumatoid arthritis with human beta defensins |
| WO2010007166A2 (en) * | 2008-07-18 | 2010-01-21 | Novozymes A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
-
2009
- 2009-07-17 NZ NZ590466A patent/NZ590466A/xx not_active IP Right Cessation
- 2009-07-17 CN CN2009801363423A patent/CN102159232A/zh active Pending
- 2009-07-17 WO PCT/EP2009/059251 patent/WO2010007165A2/en not_active Ceased
- 2009-07-17 CA CA2730674A patent/CA2730674A1/en not_active Abandoned
- 2009-07-17 EP EP09780789.5A patent/EP2320929B1/en active Active
- 2009-07-17 AR ARP090102740A patent/AR072524A1/es not_active Application Discontinuation
- 2009-07-17 MX MX2011000569A patent/MX2011000569A/es not_active Application Discontinuation
- 2009-07-17 EA EA201170218A patent/EA201170218A1/ru unknown
- 2009-07-17 KR KR1020117002473A patent/KR20110031962A/ko not_active Withdrawn
- 2009-07-17 AU AU2009272680A patent/AU2009272680A1/en not_active Abandoned
- 2009-07-17 BR BRPI0915780-8A patent/BRPI0915780A2/pt not_active IP Right Cessation
- 2009-07-17 AP AP2011005537A patent/AP2011005537A0/xx unknown
- 2009-07-17 JP JP2011517954A patent/JP2011528332A/ja active Pending
- 2009-07-17 KR KR1020117002950A patent/KR20110044863A/ko not_active Withdrawn
- 2009-07-17 US US12/504,930 patent/US20100016232A1/en not_active Abandoned
- 2009-07-20 TW TW098124404A patent/TW201004641A/zh unknown
-
2011
- 2011-01-17 CL CL2011000098A patent/CL2011000098A1/es unknown
- 2011-01-18 ZA ZA2011/00462A patent/ZA201100462B/en unknown
- 2011-01-18 IL IL210714A patent/IL210714A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011528332A (ja) | 2011-11-17 |
| EP2320929A2 (en) | 2011-05-18 |
| US20100016232A1 (en) | 2010-01-21 |
| AR072524A1 (es) | 2010-09-01 |
| NZ590466A (en) | 2012-08-31 |
| KR20110044863A (ko) | 2011-05-02 |
| BRPI0915780A2 (pt) | 2019-03-12 |
| AP2011005537A0 (en) | 2011-02-28 |
| CN102159232A (zh) | 2011-08-17 |
| CA2730674A1 (en) | 2010-01-21 |
| CL2011000098A1 (es) | 2011-10-07 |
| IL210714A0 (en) | 2011-03-31 |
| AU2009272680A1 (en) | 2010-01-21 |
| EP2320929B1 (en) | 2019-05-29 |
| TW201004641A (en) | 2010-02-01 |
| KR20110031962A (ko) | 2011-03-29 |
| MX2011000569A (es) | 2011-02-23 |
| WO2010007165A2 (en) | 2010-01-21 |
| ZA201100462B (en) | 2013-03-27 |
| WO2010007165A3 (en) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170218A1 (ru) | Лечение воспалительных заболеваний бета-дефенсинами млекопитающих | |
| EA201170219A1 (ru) | Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| EA201270575A1 (ru) | Соединения | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| EA201300730A1 (ru) | Производные индазолилтриазола | |
| EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
| EA201100765A1 (ru) | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств | |
| EA201290540A1 (ru) | Лечение заболеваний сердца | |
| PH12012501680A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| UY35470A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| EA201071057A1 (ru) | Производные азетидина и циклобутана как ингибиторы jak-киназ | |
| EA201100302A1 (ru) | Лечение диабета у пациентов, для которых лечение метформином является неприемлемым | |
| EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| MX364200B (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| NZ702334A (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| EA201291034A1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| CR20110560A (es) | Métodos de tratamiento para tumores sólidos | |
| EA201101530A1 (ru) | ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
| CR11818A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| EA201201374A1 (ru) | Лечение атаксии-телеангиэктазии | |
| EA201391154A3 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих |